Protagonist Therapeutics Announces Oral Presentation on Long

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Associatio...

Related Keywords

Ann Arbor , Michigan , United States , Spain , Madrid , Hall Goya , Kristenm Pettit , Corey Davis , Division Of Hematology Oncology , Department Of Internal Medicine , Network Of Companies , University Of Michigan , European Hematology Association , Protagonist Therapeutics Inc , Nasdaq , Protagonist Therapeutics , Presentation Title , Updated Long Term Results , Study Investigating , Hepcidin Mimetic Rusfertide , Polycythemia Vera Patients , Hematocrit Control , Therapeutic Phlebotomy , Internal Medicine , Conference Session , Abstract Details , Hepcidin Mimetic , Polycythemia Vera , Nishit Modi , Clinical Pharmacology ,